Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3559 | Self-guided exercises Wiki | 1.00 |
| drug2796 | PT-Pal Wiki | 1.00 |
| drug566 | Biological sample collection Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify immunophenotypic and genomic features of COVID-19 -related susceptibility and/or progression. The aim: for the results obtained from this study to assist in generating hypotheses for effective host-directed therapeutic interventions, to help to prioritize proposals for such interventions, and/or optimize timing for administration of host-response directed therapeutics.
Description: The incidence of mortality in the first 28 days.
Measure: Mortality Rate Among COVID-19 Patients Time: Day 1 to Day 28Description: As a measure of disease acuity and severity.
Measure: Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28 Time: Day 1 to Day 28Description: As a measure of disease acuity and severity.
Measure: Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28 Time: Day 1 to Day 28Description: Ribonucleic acid (RNA) from the nasal swab will be used to assess SARS-CoV-2 viral load.
Measure: Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28 Time: Day 1 to Day 28Description: Focus on the immune response to SARS-CoV-2, seroconversion and immunoglobulin and transitions. Antibody isotypes present in a patient specimen(s) provide information about the timing of initial exposure and may provide insight on the progression of the disease and prognosis.
Measure: Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12 Time: Up to 12 MonthsDescription: Collected as part of clinical care.
Measure: Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28 Time: Day 1 to Day 28Description: Collected as part of clinical care.
Measure: Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28 Time: Day 1 to Day 28Description: A measure of disease morbidity.
Measure: Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28 Time: Day 1 to Day 28Description: A measure of disease morbidity.
Measure: Proportion of Patients with COVID-19 with Requirement for New (Or Increased from Baseline if on Home Oxygen) Supplemental Oxygen Over Time to Day 28 Time: Day 1 to Day 28Description: A measure of disease morbidity.
Measure: Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients with COVID-19 Over Time to Day 28 Time: Day 1 to Day 28Description: Method of immune profiling and quantitating the response to COVID-19 over time.
Measure: Mechanistic: Immune Cell Frequencies and Activation Status (CyTOF) in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12 Time: Up to 12 MonthsDescription: To identify and quantitate differences in immune response associated with disease outcome.
Measure: Mechanistic: Gene Expression (Transcriptomics) in Blood Time: Up to 12 MonthsDescription: To identify and quantitate differences in immune response associated with disease outcome.
Measure: Mechanistic: Gene Expression (Transcriptomics) in Respiratory Epithelium Time: Up to 12 MonthsDescription: To identify and quantitate differences in immune response associated with disease outcome.
Measure: Mechanistic: Gene Expression (Transcriptomics) in Plasma Protein Time: Up to 12 MonthsDescription: To identify and quantitate differences in immune response associated with disease outcome.
Measure: Mechanistic: Gene expression (Transcriptomics) in Metabolic Profiling Time: Up to 12 MonthsDescription: Circulating immune biomarkers will be explored by use of the OLINK® (name of brand), a multiplex protein biomarker discovery panel.
Measure: Mechanistic: Circulating Immune Mediators Assessed by OLINK Methodology Time: Up to 12 MonthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports